Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

HIV-Associated Lipodystrophy Syndrome
Insulin Resistance
HIV Infections
Metabolic Syndrome X
Body Weight Changes

Interventions

DRUG: Rosiglitazone
DRUG: Recombinant human growth hormone + rosiglitazone

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]